According to Yakkang Biotech's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for 2 consecutive trading days on August 7 and August 10, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders and actual controllers, as of the disclosure date, the company and related parties had no significant information that should have been disclosed but not disclosed. Currently, the operation is normal, and there have been no major changes. The company reminds investors to pay attention to stock price fluctuations and trading risks, and invest rationally.

According to Yakkang Biotech's announcement, the cumulative deviation value of the company's stock price increase exceeded 30% for 2 consecutive trading days on August 7 and August 10, 2026, which is an abnormal fluctuation. After self-inspection and verification with the controlling shareholders and actual controllers, as of the disclosure date, the company and related parties had no significant information that should have been disclosed but not disclosed. Currently, the operation is normal, and there have been no major changes. The company reminds investors to pay attention to stock price fluctuations and trading risks, and invest rationally.